Aoxiang Pharmaceutical: Wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for Imatinib Mesylate Tablets issued by the National Medical Products Administration.

Aoxiang Pharmaceutical Announcement: Recently, its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. received the "Drug Registration Certificate" of Imatinib Mesylate Tablets approved and issued by the National Medical Products Administration. Imatinib Mesylate Tablets is the world's first targeted anti-tumor molecular drug, used for treating patients in the chronic phase of chronic myeloid leukemia after failure of treatment with interferon-alpha, patients in the accelerated phase or blast crisis, and patients with unresectable or metastatic malignant gastrointestinal stromal tumors.